Avalo Therapeutics (AVTX) Change in Account Payables (2014 - 2026)
Avalo Therapeutics (AVTX) posted Change in Account Payables of $219000.0 for Q1 2026, up 164.99% on a QoQ basis from -$337000.0 in Q4 2025, and down 44.97% year-over-year from $398000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Change in Account Payables (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Change in Account Payables history runs 13 years deep, the most recent figure standing at $219000.0 for Q1 2026.
- Quarterly Change in Account Payables fell 44.97% year-over-year to $219000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$325000.0 (down 38.3% YoY) and the FY2025 annual result came in at -$146000.0, up 10.43% from the prior year.
- Change in Account Payables was $219000.0 for Q1 2026 at Avalo Therapeutics, up from -$337000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.7 million in Q1 2023 and bottomed at -$4.8 million in Q2 2023.
- A 5-year average of -$177235.3 and a median of $37000.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 3027.03% in 2024, while the deepest fall reached 346.78% in 2024.
- Avalo Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then slumped by 123.83% to -$342000.0 in 2023, then sank by 346.78% to -$1.5 million in 2024, then surged by 77.95% to -$337000.0 in 2025, then surged by 164.99% to $219000.0 in 2026.
- Business Quant data shows AVTX's Change in Account Payables at $219000.0 in Q1 2026, -$337000.0 in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 219,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 219,000.00 |
| Mar 31, 2026 | 219,000.00 |
| Dec 31, 2025 | -337,000.00 |
| Dec 31, 2025 | -337,000.00 |
| Sep 30, 2025 | -1.89 Mn |
| Sep 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 398,000.00 |
| Mar 31, 2025 | 398,000.00 |
| Dec 31, 2024 | -1.53 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | -262,000.00 |
| Jun 30, 2024 | -262,000.00 |
| Mar 31, 2024 | 470,000.00 |
| Mar 31, 2024 | 470,000.00 |
| Dec 31, 2023 | -342,000.00 |
| Dec 31, 2023 | -342,000.00 |